Elanco Animal Health Incorporated · NYSE:ELAN
Elanco Animal Health — J.P. Morgan Healthcare Conference 2025
26 slides from Elanco Animal Health's conference presentation, Jan 13, 2025
Slide 1: J.P. Morgan Healthcare Conference
J.P. Morgan Healthcare Conference January 14, 2025 Jeff Simmons President & Chief Executive Officer
Slide 2: Forward-looking statements
© 2025 Elanco or its affiliates This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 (Exchange Act), including, without limitation, our expected 2024 full year and fourth quarter r
Slide 3: Launching Our Diverse Portfolio of Innovation
J.P. Morgan Healthcare Conference | January 2025 3 Six potential blockbusters on track, expected to accelerate revenue to mid -single digit (MSD) organic constant currency growth in 2025 Launching Our Diverse Portfolio of Innovation Five key updates since November earnings call: ✓ Launching and ship
Slide 4: Investment highlights
Attractive, Growing Markets Delivering Consistent, High-Impact Innovation Sustainable Revenue Growth, Margin Expansion Multiple Expansion Opportunity Positioned to Win and Gain Market Share ~$41B1 global animal health pharmaceutical industry across Pet Health ($16B) and Farm Animal ($25B) with consi
Slide 5: Animal Health: Attractive, Growing Markets with Positive Long-Term Tailwinds
© 2025 Elanco or its affiliates 5 Animal Health: Attractive, Growing Markets with Positive Long-Term Tailwinds J.P. Morgan Healthcare Conference | January 2025 Farm Animal $25B Global Industry1 Protein demand growth globally driven by GDP and expanding protein diets Producers focused on food safety,
Slide 6: Elanco at a Glance
© 2025 Elanco or its affiliates Elanco at a Glance A Global, Independent Leader Reaching the World’s Animals 1Non-GAAP financial measure. See Appendix to this presentation for more information, including GAAP to non-GAAP reconciliations. 2 Facts and figures shown are as of Dec. 31, 2023; excluding c
Slide 7: Established Foundation Focused on Animal Health
© 2025 Elanco or its affiliates Established Foundation Focused on Animal Health Acquisitions for portfolio diversity; Spin-out of Eli Lilly with 2018 IPO; Dedicated sites & systems An independent leader with an optimized cost base positioned to reach the world’s animals at scale Balanced Mix & Incre
Slide 8: Elanco's Strategy to Deliver Value to All Stakeholders
© 2025 Elanco or its affiliates n I novation Portfolio Productivity Customer Veterinarian Farmer Pet Owner IPP: Innovation, Portfolio, Productivity Elanco’s Strategy to Deliver Value to All Stakeholders, Rooted in a Deep Focus on the Customer Deliver consistent, high-impact Innovation Continuously i
Slide 9: Accelerating Topline Growth Driven by Portfolio Diversity and Innovation
© 2025 Elanco or its affiliates Accelerating Topline Growth Driven by Portfolio Diversity, Innovation Contribution and Key Growth Enablers 1YTD Data as of Sep. 30, 2024; excludes the aqua business and contract manufacturing. 2Pet Health revenue represents dogs and cats. 3Cattle revenue represents al
Slide 10: Global Pet Health Market Positioning
© 2025 Elanco or its affiliates Vision Helping pets live longer, healthier, more active lives Global Pet Health Market Positioning Strategic Framework IL-31 mAb Parasiticides Dermatology Pain & Other Therapeutics 10 Differentiated entrant into fast growing global market with robust pipeline includin
Slide 11: Global Farm Animal Strategic Framework
© 2024 Elanco or its affiliates Portfolio Comprehensive, complementary product offerings Value Beyond Product Data and analytics to drive improved outcomes Innovation Solutions to producers’ greatest challenges Price Execution Optimize value based on willingness to pay Global Farm Animal Strategic F
Slide 12: A Livestock Carbon Inset Marketplace Creating Value for Dairy Farmers
© 2025 Elanco or its affiliates A Livestock Carbon Inset Marketplace Creating Value for Dairy Farmers & Food Companies Dairy farmers now have a new value stream opportunity by using product interventions and third-party accepted protocols to monetize GHG emissions reductions via the newly establishe
Slide 13: Focused on Delivering Consistent, High-Impact Innovation
© 2025 Elanco or its affiliates 13 Focused on Delivering Consistent, High-Impact Innovation Life Cycle Management Extending the life and value of our existing brands with targeted life cycle management (LCM) is core to Elanco’s value proposition to customers and contributes to a stabilizing base LCM
Slide 14: Innovation assets, approvals and launches
14 Asset Market Focus Species Approval1 Launch2 Peak Sales Opportunity3 Commentary Experior Ammonia Reduction U.S. Beef Feedlot (Rx) First-in-class; Combo clearance approval to drive expanded use in heifers Canine Parvovirus Monoclonal AB (CPMA) U.S. Vet (Rx) First-in-class; Elanco’s first monoclona
Slide 15: Innovation Expected to Deliver Incremental $600-$700 Million of Revenue in 2025
Pet Health Farm Animal 2021 2022 2023 2024-2025 Expected1 Innovation Expected to Deliver an Incremental $600-$700 Million of Revenue in 2025 1Expected launch timing is based on regulatory timelines and internal timeline estimates for regulatory, manufacturing and supply chain. The company typically
Slide 16: Major Innovation Product: Zenrelia
© 2025 Elanco or its affiliates Major Innovation Product: Zenrelia J.P. Morgan Healthcare Conference | January 2025 Strong launch trajectory in growing canine dermatology market Momentum leading to acceleration of investment in DTC and other marketing Attractive Global Canine Dermatology Market ~$1.
Slide 17: Confidence in Zenrelia Launch Trajectory
© 2025 Elanco or its affiliates Confidence in Zenrelia Launch Trajectory 17 J.P. Morgan Healthcare Conference | January 2025 Positive launch momentum leading to acceleration of DTC into January Atopic dermatitis leading cause of veterinarian visits Positive real world efficacy supplements recently p
Slide 18: Major Innovation Product: Credelio Quattro
© 2025 Elanco or its affiliates Major Innovation Product: Credelio Quattro J.P. Morgan Healthcare Conference | January 2025 Launching into the fastest-growing segment in Animal Health Launching and shipping in January; investment expected to drive pet owner preference Emerging Endecto Market Signifi
Slide 19: Major Innovation Product: Bovaer
© 2025 Elanco or its affiliates Major Innovation Product: Bovaer Livestock carbon inset marketplace creating value for dairy farmers & CPG companies Continued progress building a new market in livestock sustainability Carbon Inset Market Providing Value ~$10M earned by producers in 2024 from monetiz
Slide 20: Financial Strength and Discipline Drive Improved Debt Profile
© 2025 Elanco or its affiliates Anticipate future capital allocation flexibility available as leverage moves below 3x Financial Strength and Discipline Drive Improved Debt Profile 1Based on the company’s 2024 full year guidance and 2025 outlook as provided on November 7, 2024. 2Comparing the Operati
Slide 21: 2025 outlook: tailwinds and headwinds
Tailwinds Innovation sales ramp to $600-$700 million with multiple drivers, including: Zenrelia, Credelio Quattro, AdTab, CPMA, Bovaer, Experior OTC Pet Health retail strength Cattle & Poultry leadership Price growth Lower interest expense Headwinds Competition in U.S. Pet Health vet clinic business
Slide 22: Launching Our Diverse Portfolio of Innovation
J.P. Morgan Healthcare Conference | January 2025 22 Six potential blockbusters on track, expected to accelerate revenue to mid -single digit (MSD) organic constant currency growth in 2025 Launching Our Diverse Portfolio of Innovation Five key updates since November earnings call: ✓ Launching and shi
Slide 23: Guidance and GAAP to non-GAAP reconciliations Appendix
Guidance and GAAP reported to non-GAAP adjusted reconciliations Appendix
Slide 24: Full Year 2024 Financial Guidance
Full Year 2024 Financial Guidance1 $ millions, except per share values 2024 Revenue $4,420 - $4,450 Reported Net Income $286 - $317 Adjusted EBITDA2 $900 - $930 Reported Diluted EPS $0.58 - $0.64 Adjusted Diluted EPS2 $0.89 - $0.95 1Represents 2024 full year guidance, as provided in the Company’s Q3
Slide 25: Full Year 2024 EPS Guidance Reconciliation
Full Year 2024 EPS Guidance Reconciliation1 Note: Numbers may not add due to rounding. 1Represents 2024 full year guidance, as provided in the Company’s Q3 2024 earnings presentation issued on November 7, 2024. 2Adjusted EPS is calculated as the sum of reported EPS and total adjustments to EPS. 25 R
Slide 26: Full Year 2024 EBITDA Guidance Reconciliation
Full Year 2024 $ millions EBITDA Guidance Reconciliation1 Note: Numbers may not add due to rounding 1Represents 2024 full year guidance, as provided in the Company’s Q3 2024 earnings presentation issued on November 7, 2024. 26 Reported Net Income $286 - $317 Net Interest Expense Approx. $235 Income
Elanco Animal Health — J.P. Morgan Healthcare Conference 2025 on 6ix